Modern Methods of Devic’s Disease Treatment
DOI:
https://doi.org/10.3889/oamjms.2020.5048Keywords:
Neuromyelitis optica, Devic’s disease, Optical neuritis, Neuromyelitis optica treatment, AquaporinAbstract
BACKGROUND: Neuromyelitis optica (NMO) (also known as opticomyelitis, Devic’s syndrome/disease) is an idiopathic inflammatory disorder of the central nervous system characterized by predominant involvement of the optic nerves, spinal cord, and extensive transverse myelitis. To date, there are no convincing clinical trials that would fully evaluate the efficacy and safety of drugs for the treatment and prevention of NMO exacerbation. Taking into account the malignant course that quickly leads to disability of young, economically active population, the issues of searching for effective methods of NMO treatment remain highly urgent.
AIM: The purpose of the study was to examine available modern methods of treatment and prevention of NMO exacerbation, which have potential and require further detailed clinical trials to ensure possible application of these treatment options in clinical practice.
MATERIALS AND METHODS: We have reviewed previously applied and modern methods of treatment. We have analyzed systematic reviews, clinical, randomized, and retrospective studies of scientific medical databases: PubMed, Cochrane, The Lancet, UpToDate, and reviews of world medical journals in Russian and English.
CONCLUSIONS: The authors concluded that there is a sufficient number of drugs and combinations of methods of Devic’s disease treatment. We were interested in combinations of rituximab (RIT) and autologous stem cell transplantation, RIT and fetal hepatocyte transplantation, and RIT and strengthening the effect by plasmapheresis sessions. However, successful implementation of these methods in clinical practice requires conducting controlled clinical trials with a larger number of patients and longer follow-up periods.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Mironenko TV. Opticomyelitis (Devic’s disease). Scientific review and own clinical observation. Int Neurol J. 2012;71(1):141-7.
Shakhov BE, Belova AN, Shalenkov IV. Opticomyelitis devica: Questions of diagnosis and a description of the case from practice. Med Almanac. 2012:20(1):165-70.
Isaikin AI, Shmidt TE, Yakhno NN. Opticomyelitis. Neurol J. 2014;5:45-51.
Bradl M, Reindl M, Lassmann H. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr Opin Neurol. 2018;31(3):325-33. https://doi.org/10.1097/wco.0000000000000551 PMid:29465432
Clinical protocol for the diagnosis and treatment of optoneuromyelitis (Devik’s disease) of the Republic of Kazakhstan Protocol code: Code (s) ICD-10:G36.0 Neuromyelitis optic [Devik’s disease] -2015 - http://www.rcrz.kz/docs/clinic_protocol/2015.
Jeffery DR. Early intervention with immunomodulatory agents in the treatment of multiple sclerosis. J Neurol Sci. 2002;197(1-2):1-8. PMid:11997060
Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443-8. https://doi.org/10.1001/archneur.65.11.noc80069 PMid:18779415
Kirgizov KI, Skorobogatova EV, Volkova EY. Experience of the HighDose Chemotherapy followed by Autologous Hematopoietic Stem Cell Transplantation (AutoHSCT) in the Patients with CNS Autoimmune Diseases; 2013.
Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol. 2013;9(1):36-42. https://doi.org/10.3988/jcn.2013.9.1.36 PMid:23346159
A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders.
Tradtrantip L, Asavapanumas N, Phuan P-W, Verkman AS (2014) Potential Therapeutic Benefit of C1-Esterase Inhibitor in Neuromyelitis Optica Evaluated In Vitro and in an Experimental Rat Model. PLoS ONE 9(9): e106824. https://doi.org/10.1371/journal.pone.0106824
Khamidulla AA. Modern aspects of the diagnosis and treatment of multiple sclerosis West Kazakhstan state medical university named after Marat Ospanov. J Neurosurg Neurol Kazakhstan. 2016;1(42):24-9. https://doi.org/10.18484/2305-0047.2018.4.496
Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci. 2018;385:192-7. https://doi.org/10.1016/j.jns.2017.12.034 PMid:29406904
Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: A randomized clinical trial. J Neurol. 2017;264(9):2003-9. https://doi.org/10.1007/s00415-017-8590-0 PMid:28831548
Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, et al. Safety and efficacy of opicinumab in acute optic neuritis: A randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):189-99. https://doi.org/10.1016/s1474-4422(16)30377-5
Yamamura T, Kleiter I, Fujihara K, Palace J. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:2114-24. https://doi.org/10.1056/nejmoa1901747
Lotan I, Charlson RW, Ryerson LZ, Levy M, Kister I. Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;39:101920. https://doi.org/10.1016/j.msard.2019.101920
Levy M. Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018;5(6):e510. https://doi.org/10.1212/nxi.0000000000000510 PMid:30345335
Kojima M, Oji S, Tanaka S. Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti- AQP4 antibody. Mult Scler Relat Disord. 2019;39:101907. https://doi.org/10.1016/j.msard.2019.101907 PMid:31931404
Cree AC, Bennett JL, Kim J, Weinshenker BG, Pittock SJ. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-63. https://doi.org/10.3410/f.736576420.793565143 PMid:31495497
Frampton JE. Correction to: Eculizumab: A review in neuromyelitis optica spectrum disorder. Drugs. 2020;80(7):729. https://doi.org/10.1007/s40265-020-01315-x PMid:32319075
Downloads
Published
How to Cite
License
Copyright (c) 2020 Grigolashvili Marina Archilovna, Kim Ekaterina Danilovna, Beisembayeva Mira Baikonyrovna, Smagulov Amirzhan Muratovich, Omarova Sholpan Kabidenovna, Biduysenov Nurdaulet Kurmashovich, Belyaev Ruslan Andreevich, Abildina Akmaral Ardakovna, Abueva Zhanna Argynovna, Aimurzina Zhanargul Nagimovna, Amanzhol Aigerim Baltalykyzy (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
